Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Expert Review of Anticancer Therapy|July 13, 2002
Hormonal treatment of endometrial carcinomaMark BaekelandtCurrent Opinion in Investigational Drugs (London, England : 2000)|November 15, 2002
Irofulven (MGI Pharma)Mark BaekelandtDiagnostic Cytopathology|November 17, 2007
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cellsBen Davidson, Mark Baekelandt, Ie-Ming ShihInternational Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|September 22, 2007
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinomaM Haysam Khouja, Mark Baekelandt, Jahn M Nesland, et al.Gynecologic Oncology|February 28, 2006
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinomaQinghua Wu, Zhenhe Suo, Gunnar B Kristensen, et al.Oncology Letters|September 12, 2012
Limitations of tissue microarrays compared with whole tissue sections in survival analysisM Haysam Khouja, Mark Baekelandt, Agkha Sarab, et al.Gynecologic Oncology|August 22, 2006
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinomaMichal Gorovetz, Mark Baekelandt, Aasmund Berner, et al.Gynecologic Oncology|August 7, 2004
E-cadherin and catenins in early squamous cervical carcinomaGregg Van de Putte, Gunnar B Kristensen, Mark Baekelandt, et al.Gynecologic Oncology|September 3, 2005
Risk grouping in stage IB squamous cell cervical carcinomaGregg Van de Putte, A Kathrine Lie, Werner Vach, et al.Gynecologic Oncology|January 31, 2004
Cyclins and proliferation markers in early squamous cervical carcinomaGregg Van de Putte, Gunnar B Kristensen, A Kathrine Lie, et al.Pageof 2